LAEKNA-B (02105) Surges Over 5% After Completing 24-Week Low-Dose Monotherapy Study Treatment Group for LAE102

Stock News10-14

According to a report, LAEKNA-B (02105) rose more than 5%, reaching 4.46% as of press time at HK$6.795, with a turnover of HK$2.3566 million.

On the news front, on October 13, LAEKNA-B announced that the group has completed the treatment of the low-dose group in the 24-week monotherapy study of LAE102. The data is consistent with the previous single ascending dose (SAD) and multiple ascending dose (MAD) study results of LAE102, demonstrating positive changes in body composition.

Notably, the completed low-dose group showed encouraging weight loss effects, with observed muscle gain and fat reduction. The 24-week treatment was well tolerated, with no serious adverse events reported, and no reports of diarrhea, muscle cramps, or acne, consistent with previously disclosed SAD and MAD study results.

The high-concentration formulation of LAE102 has recently become available, and the group has completed subject enrollment for the high-dose group to further evaluate the efficacy and safety of LAE102 at high dose levels over the 24-week treatment period.

Currently, the group is actively seeking globally capable partners to accelerate the global development and commercialization process of LAE102.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment